eGenesis Secures $191 Million in Series D Funding to Propel Kidney Transplant Innovation
eGenesis, a trailblazer in biotechnology with a focus on developing human-compatible engineered organs, has announced the successful completion of a $191 million Series D financing round. This substantial investment will propel the advancement of eGenesis’s lead product candidate, EGEN-2784, through its first-in-human clinical trials for kidney transplants. Additionally, the funds will facilitate the expansion of…